S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML O...

por Garcia-Manero, G., Winer, E. S., DeAngelo, D. J., Tarantolo, S., Sallman, D. A., Dugan, J., Groepper, S., Giagounidis, A., Götze, K., Metzeler, K. H., Li, C.-C., Zhou, L., Martinez, E., Lane, M., von Roemeling, R., Bohme, M., Kubasch, A. S., Verma, A., Platzbecker, U.
Publicado 2022